Results 151 to 160 of about 2,492,664 (191)
IRF8 Regulates Efficacy of Therapeutic Anti-CD20 Monoclonal Antibodies
European Journal of Immunology, 2022 Abstract Anti‐CD20 monoclonal antibodies such as Rituximab, Ofatumumab, and Obinutuzumab are widely used to treat lymphomas and autoimmune diseases. They act by depleting B cells, mainly through Fc‐dependent effectors functions. Some patients develop resistance to treatment but the underlying mechanisms are poorly
Françoise Porrot +2 more
exaly +6 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Ofatumumab, a Human Anti-CD20 Monoclonal Antibody
Expert Opinion on Biological Therapy, 2010Since relapse of chronic lymphocytic leukemia (CLL), and refractoriness to treatment following relapse, is inevitable after initial treatment, development of novel treatment strategies is necessary.CD20 as a therapeutic target for CLL, successes and limitations of current anti-CD20 monoclonal antibody (mAb) therapy, and implications of preclinical and ...
Anders Österborg
exaly +3 more sources
Anti-CD20 Monoclonal Antibodies: Beyond B-Cells
Blood Reviews, 2013Anti-CD20 monoclonal antibodies (MoAbs), employed in treating CD20⁺ lymphomas and autoimmune diseases, appear to have broader functions than just eradicating malignant B-cells and decreasing autoantibody production. Rituximab-induced T-cell inactivation, reported both in-vitro and in-vivo, may contribute to the increased risk of T-cell-dependent ...
Irit Avivi, Dina Stroopinsky, Tamar Katz
exaly +3 more sources
Mechanisms of killing by anti-CD20 monoclonal antibodies
Molecular Immunology, 2007CD20 is a cell-surface marker expressed on mature B cells and most malignant B cells, but not stem or plasma cells. It is an ideal target for monoclonal antibodies (mAb), such as rituximab and ofatumumab, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following mAb ...
Glennie, Martin J. +3 more
openaire +3 more sources
Anti-CD20 monoclonal antibodies in multiple sclerosis
Expert Review of Neurotherapeutics, 2016The therapeutic utility of the anti-CD20 monoclonal antibodies (mAbs) is currently being evaluated in multiple sclerosis (MS) in line with the better understanding of the role of B lymphocytes in MS pathogenesis. Area covered: We conducted a literature search using Medline/Pub Med database of basic research and available controlled trials about anti ...
Irene, Moreno Torres +1 more
openaire +2 more sources
Treatment of SLE with Anti-CD20 Monoclonal Antibody
2004Systemic lupus erythemaotsus (SLE) is an autoimmune disease involving multiple organ systems and characterized by anti-nuclear antibodies. While T cells and dendritic cells may play major roles in SLE, several lines of evidence strongly suggest a central role for B cells.
R John, Looney +2 more
openaire +2 more sources
Anti‐CD20 monoclonal antibody therapy in multiple myeloma
British Journal of Haematology, 2008SummaryCD20 is a particularly appealing target that is expressed on the surface of almost all B cells, with no significant shedding, secretion or internalization. In contrast to the demonstrated efficacy of anti‐CD20 strategies in various B‐cell lymphoproliferative disorders, the role of such therapy in multiple myeloma is undetermined and ...
Prashant, Kapoor +5 more
openaire +2 more sources
Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia
Expert Opinion on Biological Therapy, 2012The last decade has witnesd immense progress in the treatment of chronic lymphocytic leukemia (CLL). Chemoimmunotherapy (CIT) combining rituximab and fludarabine with cyclophosphamide (FCR) in the frontline setting has clearly been shown to improve outcomes in patients with CLL.
Preetesh, Jain, Susan, O'Brien
openaire +2 more sources
Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
CNS Drugs, 2020Multiple sclerosis (MS) was previously thought to be a T-cell-mediated, demyelinating disease of the central nervous system. Disease-modifying therapies targeting T cells have, indeed, shown remarkable efficacy in patients with relapsing-remitting MS.
Finn Sellebjerg +2 more
openaire +3 more sources
Treatment of Refractory Pemphigus with the Anti-CD20 Monoclonal Antibody (Rituximab)
Dermatology, 2007<i>Background:</i> Pemphigus is a severe blistering disorder caused by autoantibodies to desmogleins 1 and 3. Because some patients with pemphigus never enter into remission, new immunosuppressants are warranted. Rituximab is a chimeric monoclonal antibody binding to the CD20 antigen on B cells, which proved to be effective in recalcitrant ...
A.V. Marzano +4 more
openaire +2 more sources